TL;DR: In pharmacovigilance, document delivery is part of the compliance workflow. Teams need to review literature on a schedule, make decisions under tight deadlines, and maintain a clear record of what they reviewed. But they only need to keep a small portion of the papers they read. With DeepDyve’s LitHub platform, teams can read any of the 35 million papers in its LitStream collection in the browser without purchasing them, analyze them with the AI Research Assistant, organize the evidence in shared folders, and purchase only the PDFs they need to retain, at the publisher’s price, with no DeepDyve markup.
Literature monitoring: what the regulations require
In the EU, Good Pharmacovigilance Practices Module VI expects marketing authorization holders to monitor the scientific and medical literature for individual case safety reports (ICSRs) on their products. In practice that means a weekly search of databases such as Embase and PubMed, by active substance. A serious case has to reach the authorities within 15 days of the day you first became aware of it. If the abstract already meets the minimum criteria for a valid case, that day is the day the search was run, not the day someone finally read the paper.
The EMA runs its own Medical Literature Monitoring service for a defined list of substances and journals. If your product is on that list, the EMA search covers part of your obligation, but only for the journals and substances the service includes. Everything outside it, including local journals in the markets where you hold a license, is still yours.
In the US, 21 CFR 314.80 requires applicants to review adverse experience information from every source, foreign or domestic, and it names scientific literature explicitly. Serious, unexpected events found in the literature are subject to 15-day alert reporting.
Beyond case reports, GVP Module IX treats the literature as a signal source. Trials, observational studies, reviews, and meta-analyses can carry a safety signal even when no individual patient is described, and a good monitoring process catches those too.
Why the full-text step is hard
An abstract often does not contain enough to assess a case. To decide whether a published report is a valid ICSR you need an identifiable patient, an identifiable reporter, a suspect drug, and an adverse event. When the abstract does not have all of that, the only way to find out is to read the paper.
To get the full text, most teams buy articles one at a time. Pay-per-view prices for clinical journals run roughly $30 to $50 an article, and a weekly search on an established product can surface dozens of candidates. Our own usage data shows the demand: a steady stream of drug-safety readers retrieving individual case reports.
Where DeepDyve fits at each step
1. Read the full text on day zero, before buying anything
In LitHub, if the paper is in the LitStream collection, the reviewer opens the full text in the browser and reads it immediately. No purchase, no request queue, no waiting for a colleague with ordering rights. That matters because for a paper that turns out to describe a case, the 15-day reporting clock may already be running. The assessment starts on day zero, not two or three days into the window while an ordered PDF is in transit.
Most of those papers turn out not to describe a reportable case. Under a buy-to-evaluate workflow, each of those would be a PDF bought for ten minutes of reading. Under DeepDyve’s read-before-buy workflow, they are read, assessed, and documented without a transaction.
2. Analyze with AI on the full text you can read
For eligible papers, the AI Research Assistant works against the full text rather than the abstract. A reviewer can ask whether the paper reports an identifiable patient, which product is suspected, what the outcome was, and whether the authors attribute the event to the drug. The answers point back into the text so the reviewer can verify them.
AI availability depends on the paper, the plan, and the content’s rights. Treat assistant answers as a faster way into the paper, not as the assessment itself, and do not enter patient-identifying information from your own case files into prompts.
3. Organize the evidence behind the decision
Shared folders, tags, and annotations let the team work on the review together. Reviewers can file papers by product, tag each with the search date and the screening decision, and annotate the passage that supports it. The official record still lives in the safety database. What DeepDyve holds is the evidence: the paper and the passage that supports the decision. That makes the entry faster to write and easier to defend at inspection.
4. Buy what you must report, at publisher price
When an article becomes a case, or is needed for a periodic safety update report, the team usually needs a copy of the PDF. Partner-publisher PDFs are purchased at the publisher’s price with no DeepDyve markup. Out-of-network orders routed through CCC carry CCC’s fee.
Each purchase can carry up to three notes, such as a cost center or a sponsor’s client code. The notes print on the receipt and pass through to the CCC invoice for orders CCC fulfills, so each charge arrives already assigned to the right product or client.
5. Never buy the same article twice
Duplicate purchases are common in pharmacovigilance because the same article surfaces in searches for several products, in several weeks, and for several reviewers. DeepDyve’s enterprise plans detect when an article has already been purchased by the organization and surface the existing copy instead of charging again. Purchased partner PDFs enter the Research Archive automatically, and PDFs acquired elsewhere can be uploaded when rights allow.
6. Scale and control purchasing
For large programs, an API automates bulk purchases so that a batch of case-confirmed articles is acquired without a reviewer placing each order by hand. Spending limits let an administrator cap purchases so that a monitoring program stays inside its budget without a reviewer checking the total before each order.
What to confirm before relying on it
- Rights for regulatory submission. In the United States, a literature-based 15-day report must be accompanied by a copy of the published article. In the EU, the agency can request a copy, and the guidance itself says to take copyright restrictions into account. Partner PDFs are licensed for internal use, and DeepDyve does not verify the rights on PDFs you upload. Confirm in writing what your plan permits for submissions, and whether articles that need clearance beyond internal use should be routed through CCC.
- Coverage of your core journals. LitStream does not include Elsevier or ACS. Elsevier publishes a large share of the clinical and pharmacological literature, including The Lancet, so a pharmacovigilance team should test its actual hit list, not the collection size. Papers outside LitStream can still be purchased, but they are not readable before purchase.
- AI eligibility and data handling. Not every readable paper supports AI analysis, so test the assistant on your own recent hits. Confirm where prompts and paper text are processed, whether a third-party model provider sees them, and whether they are retained or used for training.
How DeepDyve compares on the workflow
Each row is a step in the monitoring workflow rather than a feature name. A check means the capability is documented in the vendor’s public materials as of September 25, 2026. A blank means our research did not find it documented, not that it is absent.
| Workflow need | DeepDyve | Article Galaxy | CCC RightFind |
|---|---|---|---|
| Read full text with no per-article charge | ✓ | ||
| Full text available instantly for covered content | ✓ | ✓ | ✓ |
| No vendor fee on PDFs the vendor fulfills | ✓ | ||
| Duplicate purchase detection | ✓ | ✓ | |
| Shared folders and annotations | ✓ | ✓ | ✓ |
| AI analysis on accessible full text | ✓ | ✓ | |
| Per-article rights check for sharing or submission | ✓ | ✓ | |
| API or bulk ordering | ✓ | ✓ | ✓ |
| Spending controls by user or team | ✓ | ✓ | ✓ |
How to test it in a month
One monitoring cycle is enough to know.
Take last month’s hit list. Export the articles that passed abstract screening. Check how many are readable in LitStream and how many would need purchase. That ratio is the number that decides whether read-before-buy changes your cost.
Time a case. Pick a hit that became a case. Measure the time from search result to full text in DeepDyve, and compare it with your current route.
Run the duplicate test. Have one reviewer purchase an article. On a later day, have a second reviewer find the same article and confirm they are shown the existing copy rather than a purchase button.
Build one product folder. File a week of hits, annotate one case with the search date and the decision, and have a third person reconstruct the review from the folder alone.
Ask the rights question in writing. Send DeepDyve your submission scenario and get the answer on record before the first case goes out.
FAQ
Can DeepDyve replace our safety database or literature-screening log? No. The official record of each search, screening decision, and case stays in your validated safety system or tracker. DeepDyve holds the papers, the highlighted passages, and the reviewer comments that sit behind those entries.
Does DeepDyve include Elsevier journals? No. Elsevier and ACS are not in the LitStream collection, and The Lancet is an Elsevier title. Papers from those publishers can still be ordered through the CCC RightFind integration, but they are not readable before purchase. Check your own recent hit list against the collection before relying on it.
Can we send a DeepDyve PDF to a regulator with a case report? Partner-publisher PDFs are licensed for internal use. In the United States a literature-based 15-day report must include a copy of the article, and in the EU the agency can request one, so confirm in writing what your plan permits for submissions and whether those copies should be cleared through CCC.
When does the reporting clock start for a literature case? Under European guidance, if the abstract already contains the minimum criteria for a valid case, day zero is the date the search was run. If the article had to be ordered, day zero is the day the full text makes the case valid, but the guidance expects articles to be obtained promptly.
If EMA already monitors our active substance, do we still need to search? Yes, for everything the EMA service does not cover: local journals in the markets where you hold a license, databases outside the service, and any substance not on the EMA list.
Can the AI Research Assistant do the case assessment? No. It answers questions about the full text of eligible papers so a reviewer can get to the relevant passage faster. The assessment is the reviewer’s, and patient-identifying information from your own case files should not be entered into prompts.
Can we use the Personal plan for pharmacovigilance work? No. The Personal plan is not licensed for business use. Pharmacovigilance teams need the Enterprise plan, which is also where the Research Archive, duplicate detection, purchase notes, and CCC routing live.
What happens to papers outside the LitStream collection? Enterprise users can order them through DeepDyve’s integration with CCC RightFind. CCC fulfills the order, delivers by email, and charges its own fee.
If your pharmacovigilance team is still getting full text one purchase at a time, talk to a DeepDyve client specialist about Enterprise and run one monitoring cycle against your own hit list.
DeepDyve pricing
DeepDyve features
Browse journals on DeepDyve
Pricing, features, and published terms checked September 28, 2026. Regulatory descriptions summarize general practice and are not legal advice. Customer agreements and current offers may differ.